Withdrawal of Medication in Recovered DCM

(WrecEF Trial)

Recruiting in Palo Alto (17 mi)

Overseen by Nadia Giannetti, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: McGill University

Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?

Randomized study of medication withdrawal in patients who have recovered LV function in Dilated Cardiomyopathy.

Eligibility Criteria

Inclusion Criteria

Patient diagnosed with dilated cardiomyopathy (DCM) with an initial HFrEF < 40 % at presentation.

DCM with recovered LV function to > or = to 50% documented on 2 ECHO examinations, with the most recent ECHO examination within 1 year of enrolment.

Time from initial diagnosis of DCM more or equal to 24 month.

Participant Groups

Group I: Treatment Experimental Treatment 1 Intervention

Withdrawal of beta blockers and ACE inhibitors

Group II: control Placebo Group 1 Intervention

no withdrawal, standard of care

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Royal Victoria Hospital Montreal, Canada

Who Is Running the Clinical Trial?

McGill University Lead Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre Collaborator

Jewish General Hospital Collaborator

References